SCHEMBL2870515

SCHEMBL2870515

CC1C=Cc2cc3c(cc21)-c1ccccc1C3

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.47
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 2/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SRD5A2 P31213 1/20 0.37
CYP1A2 P05177 4/20 0.37
MAOA P21397 2/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
ADRA2A P08913 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870513 0.94 PGR (0.44) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2864076 0.72 PGR (0.47) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL30912172 0.71 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL5016641 0.71 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL5058433 0.71 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL18582934 0.71 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL29924230 0.69 SMN1; SMN2 (0.61) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL3280539 0.69 SMN1; SMN2 (0.61) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2864074 0.69 PGR (0.46) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2873023 0.69 PGR (0.44) PGRALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834204-B2 Fluorene derivative, transition metal compound, catalyst for olefin polymerization, and process for producing olefin polymer MITSUI CHEMICALS, INC. (JP) 2010-11-16 US disclosed
US-20090253876-A1 Fluorene Derivative, Transition Metal Compound, Catalyst for Olefin Polymerization, and Process for Producing Olefin Polymer MITSUI CHEMICALS, INC. 2009-10-08 US disclosed
EP-1900715-A1 FLUORENE DERIVATIVE, TRANSITION METAL COMPOUND, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER Mitsui Chemicals, Inc. (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253876-A1 Fluorene Derivative, Transition Metal Compound, Catalyst for Olefin Polymerization, and Process for Producing Olefin Polymer AFF4, OR10J3, DRD1 PGR 2102/4885ALDH1A1 3472/4885MAPT 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.